Nutritional Status and Its Impact on Treatment Tolerance in Non-Small-Cell Lung Cancer Patients Receiving Osimertinib
Nutrients · 2025
DOI: 10.3390/nu17050927 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Nutrients, 2025. Verfasst von Claudia Barca-Díez und 6 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacy Department, University Hospital Complex of Vigo, 36312 Vigo, Spain. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Nutritional Status, Lung Neoplasms, Acrylamides. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Mangelernährung, Onkologische Pflege
Abstract (Originalsprache)
Background/Objectives: Non-small-cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancer cases and is a leading cause of morbidity and mortality worldwide. Between 35% and 65% of NSCLC patients experience nutritional problems or malnutrition, which significantly affects their prognosis and quality of life. This study aims to describe the nutritional status and body composition of NSCLC patients treated with osimertinib, an oral tyrosine kinase inhibitor, while also assessing the prevalence of sarcopenia, presarcopenia, and dynapenia. Additionally, we explore the relationship between dose-limiting toxicities (DLTs) and nutritional status, as well as the impact of nutritional status on quality of life using the EQ-5D scale.
Methods
A cross-sectional, observational study was conducted in 25 adult patients diagnosed with NSCLC treated with osimertinib under pharmacotherapeutic follow-up in the Pharmacy Consultations of a tertiary-level hospital. Anthropometric parameters, body composition (via bioimpedance analysis), and muscle functionality (via dynamometry) were assessed. Quality of life was evaluated using the EQ-5D scale.
Results
The results showed that 36% of patients were malnourished, 4% had sarcopenia, 8% were presarcopenic, and 20% had dynapenia. Patients with DLTs exhibited significantly lower values of fat-free mass and the fat-free mass index, suggesting a relationship between low muscle mass and increased toxicities.
Conclusions
These findings underscore the importance of early, individualized nutritional interventions in NSCLC patients treated with osimertinib to improve nutritional status and optimize oncological outcomes. Further research with larger cohorts and longitudinal designs is necessary to confirm these findings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pharmacy Department, University Hospital Complex of Vigo, 36312 Vigo, Spain.
- Pharmacy Department, University Hospital Complex of Pontevedra, 36071 Pontevedra, Spain.
- Endocrinology and Nutrition Department, University Hospital Complex of Vigo, 36312 Vigo, Spain.
- Innovation in Clinical Pharmacy Research Group (i-FARMA-Vigo), Galicia Sur Health Research Institute (IIS Galicia Sur), SERGAS-UVIGO, 36312 Vigo, Spain.
- Pharmacy Department, Hospital Ribera Povisa, 36211 Vigo, Spain.
ORCID-Profile: Noemi Martínez-López-De-Castro, Natividad Lago-Rivero
Zitieren
APA
Barca-Díez, C., Palmeiro-Carballa, R., Castro-Luaces, S., Fortes-González, M. S., Vazquez-Blanco, S., Martínez-López-De-Castro, N., & Lago-Rivero, N. (2025). Nutritional Status and Its Impact on Treatment Tolerance in Non-Small-Cell Lung Cancer Patients Receiving Osimertinib. Nutrients. https://doi.org/10.3390/nu17050927
Vancouver
Barca-Díez C, Palmeiro-Carballa R, Castro-Luaces S, Fortes-González MS, Vazquez-Blanco S, Martínez-López-De-Castro N, et al. Nutritional Status and Its Impact on Treatment Tolerance in Non-Small-Cell Lung Cancer Patients Receiving Osimertinib. Nutrients. 2025. doi:10.3390/nu17050927
BibTeX
@article{BarcaDez2025,
author = {Barca-Díez, Claudia and Palmeiro-Carballa, Regina and Castro-Luaces, Susana and Fortes-González, Maria Susana and Vazquez-Blanco, Silvia and Martínez-López-De-Castro, Noemi and Lago-Rivero, Natividad},
title = {Nutritional Status and Its Impact on Treatment Tolerance in Non-Small-Cell Lung Cancer Patients Receiving Osimertinib},
journal = {Nutrients},
year = {2025},
doi = {10.3390/nu17050927}
}
EUVIMED